Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in beta3-integrin-deficient mice
- PMID: 15574772
- DOI: 10.1158/0008-5472.CAN-04-2760
Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in beta3-integrin-deficient mice
Abstract
Tumor growth, tumor angiogenesis, and vascular endothelial growth factor (VEGF)-specific angiogenesis are all enhanced in beta(3)-integrin-null mice. Furthermore, endothelial cells isolated from beta(3)-null mice show elevated levels of Flk1 (VEGF receptor 2) expression, suggesting that beta(3)-integrin can control the amplitude of VEGF responses by controlling Flk1 levels or activity. We now show that Flk1 signaling is required for the enhanced tumor growth and angiogenesis seen in beta(3)-null mice. Moreover, beta(3)-null endothelial cells exhibit enhanced migration and proliferation in response to VEGF in vitro, and this phenotype requires Flk1 signaling. Upon VEGF stimulation, beta(3)-null endothelial cells exhibit higher levels of phosphorylated Flk1 and extracellular-related kinases 1 and 2 than wild-type endothelial cells. Furthermore, signaling via ERK1/2 is required to mediate the elevated responses to VEGF observed in beta(3)-null endothelial cells and aortic rings in vitro. These data confirm that VEGF signaling via Flk1 is enhanced in beta(3)-integrin-deficient mice and suggests that this increase may mediate the enhanced angiogenesis and tumor growth observed in these mice in vivo.
Similar articles
-
Role of the vascular endothelial growth factor isoforms in retinal angiogenesis and DiGeorge syndrome.Verh K Acad Geneeskd Belg. 2005;67(4):229-76. Verh K Acad Geneeskd Belg. 2005. PMID: 16334858 Review.
-
Beta3-integrin regulates vascular endothelial growth factor-A-dependent permeability.Arterioscler Thromb Vasc Biol. 2004 Nov;24(11):2108-14. doi: 10.1161/01.ATV.0000143857.27408.de. Epub 2004 Sep 2. Arterioscler Thromb Vasc Biol. 2004. PMID: 15345507
-
Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.Cancer Res. 2004 May 15;64(10):3586-92. doi: 10.1158/0008-5472.CAN-03-2673. Cancer Res. 2004. PMID: 15150116
-
Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?Nat Rev Cancer. 2002 Nov;2(11):826-35. doi: 10.1038/nrc925. Nat Rev Cancer. 2002. PMID: 12415253 Review. No abstract available.
-
Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins.Nat Med. 2002 Jan;8(1):27-34. doi: 10.1038/nm0102-27. Nat Med. 2002. PMID: 11786903
Cited by
-
Genetic deletion or tyrosine phosphatase inhibition of PTPRZ1 activates c-Met to up-regulate angiogenesis and lung adenocarcinoma growth.Int J Cancer. 2023 Sep 1;153(5):1051-1066. doi: 10.1002/ijc.34564. Epub 2023 Jun 1. Int J Cancer. 2023. PMID: 37260355
-
Integrin-Dependent Cell-Matrix Adhesion in Endothelial Health and Disease.Circ Res. 2023 Feb 3;132(3):355-378. doi: 10.1161/CIRCRESAHA.122.322332. Epub 2023 Feb 2. Circ Res. 2023. PMID: 36730379 Free PMC article. Review.
-
Nuclear Molecular Imaging of Cardiac Remodeling after Myocardial Infarction.Pharmaceuticals (Basel). 2022 Jan 31;15(2):183. doi: 10.3390/ph15020183. Pharmaceuticals (Basel). 2022. PMID: 35215296 Free PMC article. Review.
-
It's Time to Shift the Paradigm: Translation and Clinical Application of Non-αvβ3 Integrin Targeting Radiopharmaceuticals.Cancers (Basel). 2021 Nov 26;13(23):5958. doi: 10.3390/cancers13235958. Cancers (Basel). 2021. PMID: 34885066 Free PMC article. Review.
-
Improved Immunotherapy Efficacy by Vascular Modulation.Cancers (Basel). 2021 Oct 17;13(20):5207. doi: 10.3390/cancers13205207. Cancers (Basel). 2021. PMID: 34680355 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Miscellaneous
